Skip to main content
. Author manuscript; available in PMC: 2016 Jul 8.
Published in final edited form as: Oncogene. 2015 Sep 28;35(23):2971–2978. doi: 10.1038/onc.2015.362

Figure 6. JI6 effectively inhibit the proliferation of FLT3-D835Y-transformed HCD-57 in immunodeficient mice and prolongs the animal survival.

Figure 6

NSG mice were engrafted with FLT3-D835Y-transformed HCD-57 cells through intravenous injection. JI6 treatment was started 24 hours later by intraperitoneal injection of JI6 at a single daily dose of 15 mg/kg for 3 weeks. (A) Spleen weights of engrafted mice after 3 weeks of treatment with JI6 or vehicle. Error bars denote standard deviation (n≥7 as indicated). (B) Kaplan-Meier analysis of animal survival. Mice were treated with JI6 or vehicle from day 1 to day 21.